Results of Studies by Three Key Opinion Leader Laboratories
Demonstrate Significant Advantages in Drug Discovery, Cancer
Detection, and in the Analysis of Microorganism Diversity in
Soil.
South Easton, MA -- May 4, 2015 -- InvestorsHub NewsWire --
Pressure BioSciences, Inc. (OTCQB:
PBIO) (“PBI” or the “Company”), a leader in the development and
sale of broadly enabling sample preparation solutions using
pressure cycling technology (“PCT”)-based instruments and
consumables to the worldwide life sciences industry, today
announced the publication of three important articles in scientific
journals by key opinion leaders in proteomics and genomics.
The Company believes the articles highlight the clear advantages
its patented PCT platform offers research scientists working in the
areas of drug discovery and design, cancer detection, and the
analysis of microorganism populations in soil. The Company
also believes that the data offer compelling reasons why its
PCT-based instruments and consumables may soon become a
“need-to-have” tool in these and other areas of the life
sciences.
Use of pressure cycling technology for cell lysis and recovery
of bacterial and fungal communities from soil; Dr. Emily Bruner,
Dr. Patricia Okubara & colleagues, Washington State University
and the USDA-ARS in Pullman WA and Pendleton, OR, BioTechniques,
April 2015.
- Authors used the Barocycler NEP3229 instrument and PULSE Tubes
(PBI)
- The efficacy and bias of three cell lysis methods were compared
for direct DNA soil extraction
- PCT extracted DNA from a greater number of unique bacterial and
fungal species, including microorganisms not found using
traditional mechanical lysis methods (greater diversity)
- The determination of microorganism diversity in soil is
critical for successful crop growth and pestilence control; this
study shows PCT may be a valuable alternative to current lysis
methods
Structure-relaxation mechanism for the response of T4 lysozyme
cavity mutants to hydrostatic pressure; Dr. Michael Lerch, Dr.
Wayne Hubbell & colleagues, UCLA, PNAS, April 2015.
- Authors used the Barocycler HUB880 and HUB440 instruments and
ceramic pressure cells (PBI)
- High pressure is emerging as a powerful tool for understanding
protein structure and function
- Results provide direct evidence of the different ways proteins
can respond to pressure
- Protein response to pressure may have profound implications in
drug design and development
Rapid mass spectrometric conversion of tissue biopsy samples
into permanent quantitative digital proteome maps; Dr. Tiannan Guo,
Dr. Ruedi Aebersold, and colleagues, ETH Zurich Switzerland, Turku
Finland, Heidelberg Germany, and St. Gallen Switzerland, Nature
Medicine, March 2015.
- Authors used a prototype PCT-HD (Barocycler NEP2320 and
MicroTubes) system (PBI)
- New method using PCT is described for high-throughput,
quantitative, and highly reproducible proteomic analyses of tissue
biopsies with unprecedented speed and precision (“PCT-SWATH”)
- Authors expect wide applications of PCT-SWATH in personalized
medicine
- Authors believe that PCT-SWATH (aka PCT-HD) may ultimately
achieve clinical adoption
Dr. Nathan Lawrence, Vice President of Marketing and Sales for
PBI, commented: “We are very pleased with the recently published
studies from each of these three groups. We consider each a key
opinion leading laboratory in their area of focus. We believe their
studies show the clear advantages of the PCT platform in testing
soil for microbial populations, for expanding our understanding of
the complexity of protein structure and function to enable better
drug discovery and development, and for developing a new,
cutting-edge method to enhance the analysis of tissue biopsies
using unprecedented speed and precision.”
Dr. Lawrence continued: “We also believe their results will lead
to additional applications of the PCT platform. These include
the potential to expand the power of PCT from its current focus in
biological research laboratories, which we have just begun to
enter, to the very large, exciting, and potentially highly
profitable clinical laboratory setting.”
Dr. Lawrence concluded: “It is important to note that all three
laboratories used different PCT instruments and consumables.
Not only have the results of their studies helped to support the
efficacy of the PCT platform in such varied fields of use as
agriculture, drug discovery, and cancer detection, but their work
has also showcased the enormous breadth of PCT applications,
instruments, and consumable products.”
Mr. Richard T. Schumacher, President and CEO of PBI, said: “We
believe the commercial implications of these three studies, along
with the environmental epidemiology applications of the new
high-throughput Barozyme HT48 System reported recently by Dr.
William Funk of Northwestern University, are very large and
exciting. Our expanding product portfolio has helped us achieve
measurable revenue growth over the past three years. As we begin to
significantly add to our sales and marketing capabilities for the
first time since 2008, we believe our broad PCT products and
applications portfolio will manifest itself in even more
significant revenue growth in 2015 and beyond.”
About PCT-HD
The PCT-HD System combines two of the Company’s unique products:
the recently released, patent-pending µPestle consumable with an
enhanced Barocycler NEP2320 instrument. This combination
enables faster, less cumbersome and higher quality homogenization,
extraction, and digestion of proteins. PCT-HD was developed
by the Company’s scientists and engineers in collaboration with
Professor Ruedi Aebersold and Dr. Tiannan Guo of the Institute of
Molecular Systems Biology, ETH Zurich, and the University of
Zurich, both in Zurich, Switzerland. Drs. Aebersold and Guo
combined PCT-HD with AB Sciex’s SWATH-Mass Spectrometry – calling
the resulting method “PCT-SWATH”. This protocol can yield
analytical results within 12 hours from the start of processing
tissue. Although Drs. Aebersold and Guo developed protocols
for the combination of PCT-HD with SWATH-MS, the PCT-HD System is
not limited to any specific mass spectrometer or method of data
analysis. Subsequently, the PCT-HD System can provide most
researchers with unprecedented speed and reproducibility for
biomarker discovery, regardless of the mass spectrometry method
used.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (“PBI”) (OTCQB:
PBIO) develops, markets, and sells proprietary laboratory
instrumentation and associated consumables to the estimated $6
billion life sciences sample preparation market. Our products are
based on the unique properties of both constant (i.e., static) and
alternating (i.e., pressure cycling technology, or PCT) hydrostatic
pressure. PCT is a patented enabling technology platform that uses
alternating cycles of hydrostatic pressure between ambient and
ultra-high levels to safely and reproducibly control bio-molecular
interactions. To date, we have installed over 250 PCT systems in
approximately 160 sites worldwide. There are over 100 publications
citing the advantages of the PCT platform over competitive methods,
many from key opinion leaders. Our primary application development
and sales efforts are in the biomarker discovery and forensics
areas. Customers also use our products in other areas, such as drug
discovery & design, bio-therapeutics characterization, soil
& plant biology, vaccine development, histology, and
counter-bioterror applications.
Forward Looking Statements
Statements contained in this press release regarding PBI's
intentions, hopes, beliefs, expectations, or predictions of the
future are "forward-looking'' statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
are based upon the Company's current expectations, forecasts, and
assumptions that are subject to risks, uncertainties, and other
factors that could cause actual outcomes and results to differ
materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include,
but are not limited to, the risks and uncertainties discussed under
the heading "Risk Factors" in the Company's Annual Report on Form
10-K for the year ended December 31, 2014, and other reports filed
by the Company from time to time with the SEC. The Company
undertakes no obligation to update any of the information included
in this release, except as otherwise required by law.
For more information about PBI and this press release, please
click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter
Investor Contacts:
Richard T. Schumacher, President and CEO
(508) 230-1828 (T)
Nathan P. Lawrence, Vice President, Marketing and
Sales (508) 230-1829
(F)